Table 2.

Pre- and post-intervention of clinical outcome measures.

	rTMS+MI group	rTMS group	P-value
	n = 21	n = 21
PRIMARY OUTCOMES, MEAN ± SD
WMFT
Baseline	34.86 ± 6.68	34.43 ± 10.50	0.879
Week 2	54.10 ± 8.16###**	43.62 ± 10.3##	0.001
Week 4	52.90 ± 9.57###**	42.42 ± 10.14#	0.002
SECONDARY OUTCOMES, MEAN ± SD
UE-FMA
Baseline	37.19 ± 5.78	35.86 ± 7.80	0.542
Week 2	50.52 ± 6.00###**	43.33 ± 7.86##	0.002
Week 4	49.24 ± 6.52###**	42.14 ± 7.81##	0.003
MBI
Baseline	64.81 ± 5.51	63.00 ± 9.29	0.458
Week 2	86.90 ± 5.61###***	72.57 ± 8.50##	0.000
Week 4	86.04 ± 6.33###***	72.24 ± 9.51##	0.000
BBT
Baseline	5.95 ± 3.70	6.05 ± 6.50	0.955
Week 2	18.42 ± 6.21###**	12.05 ± 7.66#	0.006
Week 4	17.67 ± 6.31###**	11.43 ± 7.50#	0.007

^#p < 0.05 (compared with baseline).

^##< 0.01 (compared with baseline).

^**p < 0.01 (compared with rTMS group).

^###p < 0.001 (compared with baseline).

^***p < 0.001 (compared with rTMS group).

p-value (rTMS+MI group compared with rTMS group).

WMFT, wolf motor function test; UE-FMA, Fugl-Meyer Assessment Upper Extremity; MBI, modified Barthel index; BBT: box and block test.